Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Anti‐Granulocyte Antibody Screening with Extracted Granulocyte Antigens by a Micro‐Mixed Passive Hemagglutination Method

Identifieur interne : 000623 ( Istex/Curation ); précédent : 000622; suivant : 000624

Anti‐Granulocyte Antibody Screening with Extracted Granulocyte Antigens by a Micro‐Mixed Passive Hemagglutination Method

Auteurs : Nobuo Araki [Japon] ; Yoshisuke Nose [Japon] ; Masatoshi Kohsaki [Japon] ; Hisashi Mito [Japon] ; Kazuhiko Ito [Japon]

Source :

RBID : ISTEX:CB85D600961DE41FB25B4CE65AFA2236265D3872

Abstract

Background and Objectives: Serologic tests for granulocyte antibodies, i.e., the granulocyte agglutination test and the granulocyte immunofluorescence test, require panels of typed granulocytes that cannot be preserved for more than a few hours. We have developed a new method in which granulocyte antigens, extrcated into saline containing 3% sucrose, are coated onto U‐type Terasaki plates. With this new method, we evaluated the micro‐mixed passive hemagglutination test (EG‐MPHA) for screening for granulocyte antibodies. Materials and Methods: We tested the ability of the EG‐MPHA to detect granulocyte antigens using 5 human antibodies specific for NA1, NA2, NB1, 5b, and Sara, and 8 different monoclonal antibodies for NA1, CD11a, CD11b, CD13, CD16, CD18 and HLA class I. Sera from 94 alloimmunized patients were screened by the chloroquine‐treated EG‐MPHA method. Results: Na1, NA2, NB1, 5b, Sara, CD11a, CD11b, CD13, CD16, CD18 and HLA class I antigens were present in the extracted granulocyte antigen preparation. CD11b and HLA class I antigens were removed when the extracted granulocyte antigens were treated with chloroquine. Granulocyte antibody screening of sera from alloimmunized patients showed that approximately 30% of the anti‐HLA‐positive for granulocyte antibody by the chloroquine‐treated EG‐MPHA. The extracted granulocyte antigen panels could be stored frozen for at least 1 year at −80°C. Conclusion: This new method is preferable for screening for granulocyte antibodies. In addition, it has the advantage of requiring only 5 μl of serum for each test.

Url:
DOI: 10.1046/j.1423-0410.1999.7710044.x

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:CB85D600961DE41FB25B4CE65AFA2236265D3872

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Anti‐Granulocyte Antibody Screening with Extracted Granulocyte Antigens by a Micro‐Mixed Passive Hemagglutination Method</title>
<author>
<name sortKey="Araki, Nobuo" sort="Araki, Nobuo" uniqKey="Araki N" first="Nobuo" last="Araki">Nobuo Araki</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Nose, Yoshisuke" sort="Nose, Yoshisuke" uniqKey="Nose Y" first="Yoshisuke" last="Nose">Yoshisuke Nose</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Kohsaki, Masatoshi" sort="Kohsaki, Masatoshi" uniqKey="Kohsaki M" first="Masatoshi" last="Kohsaki">Masatoshi Kohsaki</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Mito, Hisashi" sort="Mito, Hisashi" uniqKey="Mito H" first="Hisashi" last="Mito">Hisashi Mito</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Ito, Kazuhiko" sort="Ito, Kazuhiko" uniqKey="Ito K" first="Kazuhiko" last="Ito">Kazuhiko Ito</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CB85D600961DE41FB25B4CE65AFA2236265D3872</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1046/j.1423-0410.1999.7710044.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-Q0C5Q626-P/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000623</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000623</idno>
<idno type="wicri:Area/Istex/Curation">000623</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Anti‐Granulocyte Antibody Screening with Extracted Granulocyte Antigens by a Micro‐Mixed Passive Hemagglutination Method</title>
<author>
<name sortKey="Araki, Nobuo" sort="Araki, Nobuo" uniqKey="Araki N" first="Nobuo" last="Araki">Nobuo Araki</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Nose, Yoshisuke" sort="Nose, Yoshisuke" uniqKey="Nose Y" first="Yoshisuke" last="Nose">Yoshisuke Nose</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Kohsaki, Masatoshi" sort="Kohsaki, Masatoshi" uniqKey="Kohsaki M" first="Masatoshi" last="Kohsaki">Masatoshi Kohsaki</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Mito, Hisashi" sort="Mito, Hisashi" uniqKey="Mito H" first="Hisashi" last="Mito">Hisashi Mito</name>
<affiliation wicri:level="1">
<mods:affiliation>Hyogo Red Cross Blood Center, Hyogo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Hyogo Red Cross Blood Center, Hyogo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Ito, Kazuhiko" sort="Ito, Kazuhiko" uniqKey="Ito K" first="Kazuhiko" last="Ito">Kazuhiko Ito</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Transfusion Medicine, Kyoto University Hospital, Kyoto</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Vox Sanguinis</title>
<title level="j" type="alt">VOX SANGUINIS</title>
<idno type="ISSN">0042-9007</idno>
<idno type="eISSN">1423-0410</idno>
<imprint>
<biblScope unit="vol">77</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="44">44</biblScope>
<biblScope unit="page" to="51">51</biblScope>
<biblScope unit="page-count">8</biblScope>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="1999-08">1999-08</date>
</imprint>
<idno type="ISSN">0042-9007</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0042-9007</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Background and Objectives: Serologic tests for granulocyte antibodies, i.e., the granulocyte agglutination test and the granulocyte immunofluorescence test, require panels of typed granulocytes that cannot be preserved for more than a few hours. We have developed a new method in which granulocyte antigens, extrcated into saline containing 3% sucrose, are coated onto U‐type Terasaki plates. With this new method, we evaluated the micro‐mixed passive hemagglutination test (EG‐MPHA) for screening for granulocyte antibodies. Materials and Methods: We tested the ability of the EG‐MPHA to detect granulocyte antigens using 5 human antibodies specific for NA1, NA2, NB1, 5b, and Sara, and 8 different monoclonal antibodies for NA1, CD11a, CD11b, CD13, CD16, CD18 and HLA class I. Sera from 94 alloimmunized patients were screened by the chloroquine‐treated EG‐MPHA method. Results: Na1, NA2, NB1, 5b, Sara, CD11a, CD11b, CD13, CD16, CD18 and HLA class I antigens were present in the extracted granulocyte antigen preparation. CD11b and HLA class I antigens were removed when the extracted granulocyte antigens were treated with chloroquine. Granulocyte antibody screening of sera from alloimmunized patients showed that approximately 30% of the anti‐HLA‐positive for granulocyte antibody by the chloroquine‐treated EG‐MPHA. The extracted granulocyte antigen panels could be stored frozen for at least 1 year at −80°C. Conclusion: This new method is preferable for screening for granulocyte antibodies. In addition, it has the advantage of requiring only 5 μl of serum for each test.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000623 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000623 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:CB85D600961DE41FB25B4CE65AFA2236265D3872
   |texte=   Anti‐Granulocyte Antibody Screening with Extracted Granulocyte Antigens by a Micro‐Mixed Passive Hemagglutination Method
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021